Regulatory Advocacy

The AAO-HNS has a long history of working closely with regulatory agencies (e.g., Centers for Medicare & Medicaid Services, U.S. Food and Drug Administration) to maintain our visibility and credibility with national representatives regarding federal regulatory issues.

We believe that advocacy is the key to defining the future of otolaryngology. Federal regulatory advocacy is a top priority of the AAO-HNS.

Academy Comments on Proposed 2017 Physician Fee Schedule
On September 6, the Academy submitted comments to CMS regarding the 2017 Proposed Medicare Physician Fee Schedule. Topics addressed include: practice expense adjustments; proposed global surgical data collection requirements; Appropriate Use Criteria for Advanced Diagnostic Imaging requirements, modifications to the Qualified Clinical Data Registry (QCDR) qualification requirements, and updates to the Value Based Modifier and Physician Feedback Programs.

Academy Comments on Proposed CY 2017 HOPPS
On September 6, the Academy has submitted comments on the proposed rule for CY 2017 Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory Surgical Center (ASC) Payment Rate. The Academy addressed: point-of-care imaging access for patients, Appropriate Use Criteria for Advanced Diagnostic Imaging requirements, and changes to Ambulatory Payment Classifications assignments.

Academy Comments to CMS on MIPS and APM Proposed Rule
On June 27, the Academy submitted comments to Centers for Medicare & Medicaid Services (CMS) in response to the Merit-based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Proposed Rule. The Academy commented on the consolidation of existing quality programs into MIPS; the accelerated reporting timeline for physicians; RegentSM and quality measure reporting mechanisms; the complexity of the MIPS scoring system; and the restrictive Advanced APM definition.